Lurbinectedin Approved: Metastatic Small-Cell Lung Cancer

The FDA has granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer (SCLC) experiencing disease progression on or after platinum-based chemotherapy. The efficacy of lurbinectedin, a selective inhibitor of oncogenic transcription, was investigated in a multinational, single-arm, open-label phase 2 basket trial, PM1183-B-005-14 (Study B-005; NCT02454972), which enrolled adults with SCLC previously treated with only one chemothe...
Continue reading

Racial, Age-Related Disparities in Lung Cancer Treatment

A new study reports that only 62.1% of US patients with lung cancer receive treatment that adheres to guidelines, and elderly and non-Hispanic black patients are disproportionately represented among those whose cancer is undertreated. For the study, now published in Annals of the American Thoracic Society, the researchers evaluated whether 441,812 lung cancer cases in the US National Cancer Database diagnosed between 2010 and 2014 received treatment that adhered to the National Comprehensive Can...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.